Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 4, 2014, Pages 363-373

  Seirafi, M ^a,b   De Vroey, B ^c   Amiot, A ^a   Seksik, P ^d   Roblin, X ^e   Allez, M ^f   Peyrin Biroulet, L ^g   Marteau, P ^h   Cadiot, G ⁱ   Laharie, D ^j   Boureille, A ^k   De Vos, M ^l   Savoye, G ^m   Rahier, J F ⁿ   Carbonnel, F ^o   Bonaz, B ^p   Colombel, J F ^c   Bouhnik, Y ^a  

^a BEAUJON HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL NORD   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CHU NANCY BRABOIS   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ SERVICE DE DERMATOLOGIE   (France)

^j HAUT LÉVÊQUE HOSPITAL   (France)

^k Institute of Digestive Tract Diseases   (France)

^l Ziekenhuis University   (Belgium)

^m ROUEN UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^o BICÊTRE HOSPITAL   (France)

^p GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ALLERGIC REACTION; APPLICATION SITE ECZEMA; ARTHRALGIA; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FETUS DEATH; FETUS OUTCOME; GENITAL HERPES; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVE BIRTH; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN DEATH; NEWBORN INFECTION; NEWBORN JAUNDICE; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSORIASIS; RECURRENT INFECTION; RETROSPECTIVE STUDY; SMOKING; SPONTANEOUS ABORTION; THERAPEUTIC ABORTION; TOXOPLASMOSIS; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MULTIVARIATE ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; REGISTRIES; SEVERITY OF ILLNESS INDEX; SMOKING; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84904439203     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12833     Document Type: Article

References (37)

1. Peyrin-Biroulet L, Deltenre P, De Suray N, et al,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
2. Mahadevan U, Hakimian S,. Pregnancy outcomes in women with inflammatory bowel disease: a population based cohort study. Gastroenterology 2005; 128 (Suppl. 2): A322-3.
3. Cornish JA, Tan E, Teare J, et al,. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830-7.
4. Mahadevan U, Sandborn WJ, Li DK, et al,. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study of Northern California. Gastroenterology 2007; 133: 1106-12.
5. Nguyen GC, Boudreau H, Harris ML, et al,. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2009; 7: 329-34.
6. Dominitz JA, Young JC, Boyko EJ, et al,. Outcomes in infants born to mothers with inflammatory bowel disease: a population based cohort study. Am J Gastroenterol 2001; 96: 635-43.
7. Kornfeld D, Cnattingius S, Ekbom A,. Pregnancy outcomes in women with inflammatory bowel disease: a population based cohort study. Am J Obstet Gynecol 1997; 177: 942-6.
8. Baird DD, Narendranathan M, Sandler RS, et al,. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990; 99: 987-94.
9. Simister NE,. Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-9.
10. Van der Woude CJ, Kolacek S, Dotan I, et al,.; European Crohn's Colitis Organisation (ECCO). European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4: 493-510.
11. Mahadevan U, Cucchiara S, Hyams JS, et al,. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23.
12. Zelinkova Z, de Haar C, de Ridder L, et al,. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-8.
13. Vasiliauskas EA, Church JA, Silvermann N, et al,. Case report: evidence of transplacental transfer of maternally administrated infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-6.
14. Mahadevan U, Wolf DC, Dubinsky M, et al,. Placental transfer of anti-tumor necrosis agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-92.
15. Ternant D, Mulleman D, Degenne D, et al,. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28: 169-74.
16. Mahadevan U, Abreu M,. Certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology 2009; 136 (5 Suppl. 1): A960.
17. Lichtenstein G, Cohen RD, Feagan BG, et al,. Safety of infliximab in Crohn's disease: data from the 5000-patients TREAT registry. Gastroenterology 2004; 126 (Suppl.): A54.
18. Katz JA, Antoni C, Keenan GF, et al,. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
19. Schnitzler F, Fidder H, Ferrante M, et al,. Outcome of pregnancy with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-54.
20. Johnson DL, Jones KL, Chambers CD, et al,. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology 2009; 136: A-27.
21. Casanova MJ, Chaparro M, Domènech E, et al,. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease Am J Gastroenterol 2013; 108: 433-440. doi: 10.1038/ajg.2012.430
22. Nielsen OH, Loftus EV Jr, Jess T,. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11: 174.
23. Mahadevan U, Martin C, Sandler RS, et al,. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012; 142 (5 Suppl. 1): S-149.
24. Coelho J, Beaugerie L, Colombel JF, et al,. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study. Gut 2011; 60: 198-203.
25. Satsangi J, Silverberg MS, Vermeire S, Colombel JF,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
26. World Health Organization. International statistical classification of diseases and related health problems, 10th revision. http://apps.who.int/ classifications/icd10/browse/2010/en.
27. Norgard B, Hundborg HH, Jacobses BA, et al,. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007; 102: 1947-54.
28. Nielsen OH, Andreasson B, Bondesen S, et al,. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735-42.
29. Fonager K, Sorensen HT, Olsen J, et al,. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 2426-30.
30. Bortoli A, Pedersen N, Duricova D, et al,. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011; 34: 724-34.
31. Van AG, Dignass A, Reinisch W, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
32. Van Assche G, Dignass A, Bokemeyer B, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: special situations. J Crohns Colitis 2013; 7: 1-33.
33. Mahadevan U,. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006; 55: 1198-206.
34. De Vigan C, Khoshnood B, Lhomme A, et al,. Prevalence and prenatal diagnosis of congenital malformations in the Parisian population: twenty years of surveillance by the Paris registry of congenital malformations. J Gynecol Obstet Biol Reprod (Paris) 2005; 34: 8-16.
35. Jürgens M, Brand S, Filik L, et al,. Safety of Adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis 2010; 16: 1634-6.
36. Oussalah A, Bigard M-A, Peyrin-Biroulet L,. Certolizumab use in pregnancy. Gut 2009; 58: 608.
37. Zelinkova Z, van der Ent C, Bruin KF, et al,. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of Inflammatory Bowel Disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11: 318-21.